Use of proton pump inhibitors and risk of pancreatic adenocarcinoma: A case-control study based on the French national health data system (SNDS)

被引：0

作者：

Lassalle, Marion ^{[1
,2
]}

Le Tri, Thien ^{[1
,2
]}

Afchain, Pauline ^{[3
]}

Camus-Duboc, Marine ^{[4
]}

Kirchgesner, Julien ^{[5
]}

Zureik, Mahmoud ^{[6
]}

Dray-Spira, Rosemary ^{[1
,2
]}

机构：

[1] French Natl Agcy Safety Med & Hlth Prod ANSM, EPI PHARE Epidemiol Hlth Prod, St Denis, France

[2] French Natl Hlth Insurance CNAM, St Denis, France

[3] Hop St Antoine, AP HP, Dept Med Oncol, Paris, France

[4] Sorbonne Univ, Ctr Rech St Antoine, UMRS 938, Paris, France

[5] Sorbonne Univ, INSERM, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France

[6] French Natl Agcy Safety Med & Hlth Prod & French, EPI PHARE, Epidemiol Hlth Prod, St Denis, France

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：14 / 15

页数：2

共 50 条

[21] Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study
Zipursky, Jonathan
Macdonald, Erin M.
Hollands, Simon
Gomes, Tara
Mamdani, Muhammad M.
Paterson, J. Michael
Lathia, Nina
Juurlink, David N.
PLOS MEDICINE, 2014, 11 (09)
[22] The association between proton pump inhibitor use and the risk of tuberculosis: A case-control study
Song, Hyun Jin
Park, Haesuk
Park, Susan
Kwon, Jin-Won
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (06) : 830 - 839
[23] Proton pump inhibitor use as a risk factor for Enterobacteriaceal infection: a case-control study
Cunningham, R.
Jones, L.
Enki, D. G.
Tischhauser, R.
JOURNAL OF HOSPITAL INFECTION, 2018, 100 (01) : 60 - 64
[24] Proton Pump Inhibitors Are Associated with Increased Risk of Psoriasis: A Nationwide Nested Case-Control Study
Li, Cheng-Yuan
Dai, Ying-Xiu
Chang, Yun-Ting
Bai, Ya-Mei
Tsai, Shih-Jen
Chen, Tzeng-Ji
Chen, Mu-Hong
DERMATOLOGY, 2021, 237 (06) : 884 - 890
[25] Use of proton pump inhibitors and risk of severe COVID-19: A case-control study in US Medicare beneficiaries
Mosholder, Andrew
Izurieta, Hector S.
Zhang, Rongmei
Shangguan, Shanlai
Lu, Yun
Akhtar, Sandia
Wernecke, Michael
He, Jiwei
Chillarige, Yoganand
Feng, Yuhui
Avagyan, Armen
Leishear, Kira
Forshee, Richard A.
MaCurdy, Thomas E.
Kelman, Jeffery A.
Graham, David J.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 72 - 72
[26] Assessment of proton pump inhibitors utilization and associated risk of kidney disease: A case-control study
Amarnath, Rajesh Nanda
Vijaykumar, T. M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 420 - 420
[27] Proton pump inhibitors and amyotrophic lateral sclerosis: A case-control study
Tortorella, Maria Eduarda Cardoso
Alves, Ines
Gromicho, Marta
Santos, Miguel Oliveira
de Carvalho, Mamede
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 457
[28] Diabetic Nephropathy and Proton Pump inhibitors - Pilot Case-Control Study
Raj, Jeffrey Pradeep
Pinto, Reevan Winston
Tomy, Suraj Kallarakal
Kulkarni, Shruthi M.
INDIAN JOURNAL OF NEPHROLOGY, 2022, 32 (02) : 127 - 131
[29] Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case-control study
Xiong, Jianping
Wang, Yaqin
Xu, Weiyu
Liu, Zhisong
Wang, Haochen
Zhang, Zhiyuan
Han, Yanjing
Yin, Chao
Cao, Shasha
Yang, Zheran
Su, Tianhao
Wei, Jian
Chen, Guang
Jin, Long
LIVER INTERNATIONAL, 2020, 40 (11) : 2848 - 2857
[30] Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort
Berthe, Pauline
Scailteux, Lucie-Marie
Lescoat, Alain
Staumont, Delphine
Coiffier, Guillaume
Gueret, Pierre
Dupuy, Alain
Oger, Emmanuel
Droitcourt, Catherine
BMJ OPEN, 2022, 12 (09):

← 1 2 3 4 5 →